Short-term treatment and sustained virologic response in two chronic hepatitis C cases

Kronik hepatit C infeksiyonunda standart tedavi genotip 1 ile enfekte hastalarda pegile interferon-alfa (Peg-IFN-α) ve ribavirin kombinasyonunun 48 hafta uygulanmasıdır. Genotip 2 ve 3 enfeksiyonlarında 24 haftalık konvansiyonel interferon ve ribavirin kombinasyonu ya da ribavirinle birlikte veya tek başına uygulanan Peg-IFN-α tedavisi önerilmektedir. Biz burada antiviral tedavinin önerilen süreden daha erken sonlandırılmasına rağmen kalıcı viral yanıt elde edilmiş, genotipi bilinmeyen iki kronik hepatit C olgusunu sunduk.

Kronik hepatit C enfeksiyonlu iki olguda kısa süreli tedavi ve kalıcı virolojik yanıt

The standard treatment for chronic hepatitis C infection is the combination of pegylated interferon-alpha (Peg-IFN-α) and ribavirin for 48 weeks in patients infected with genotype-1. In genotype-2 or -3 infections, treatment by either conventional IFN-α and ribavirin or Peg-IFN-α with or without ribavirin for 24 weeks is recommended. We hereby report two cases of chronic hepatitis C infection whose genotypes are not specified, with sustained virological response despite early discontinuation of antiviral treatment.

PDF

___

1) Department of Veterans Affairs Hepatitis C Resource Center, Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol 2006;101:2360-78.
2) Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615-33.
3) Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
4) Craxì A, Cammà C. Treating patients with HCV genotype 1 and low viraemia: more than meets the eye. J Hepatol 2006;44:4-7.
5) Firpi RJ, Nelson DR. Current and future hepatitis C therapies. Arch Med Res 2007;38:678-90.
6) Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005;54:858-66.
7) Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
8) Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
9) McHutchison JG, Shad JA, Gordon SC, Morgan TR, Ling MH, Garaud JJ, et al. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat 2001;8:414-20.
10) Ferenci P, Bergholz U, Laferl H, Scherzer TM, Maieron A, Gschwantler M, et al. 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 ‘super-responders'. J Hepatol 2006;44(Suppl 2):S6.
11) Abacioglu YH, Davidson F, Tuncer S, Yap PL, Ustacelebi S, Yulug N, et al. The distribution of hepatitis C virus genotypes in Turkish patients. J Viral Hepat 1995;2:297-301.
12) Yildiz E, Oztan A, Sar F, Pinarbasi E, Cetin-Atalay R, Akkiz H, et al. Molecular characterization of a full genome Turkish hepatitis C virus 1b isolate (HCV-TR1): a predominant viral form in Turkey. Virus Genes 2002;25:169-77.
13) Bozdayi G, Rota S, Verdi H, Derici U, Sindel S, Bali M, et al. The presence of hepatitis C virus (HCV) infection in hemodialysis patients and determination of HCV genotype distribution. Mikrobiyol Bul 2002;36:291-300.
14) Altuglu I, Soyler I, Ozacar T, Erensoy S. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis 2008;12:239-44.
15) Nousbaum JB, Cadranel JF, Savary O, Legrand MC, Dumouchel P, Gouérou H. Sustained virological response after a short course of treatment with interferon and ribavirin in two chronic hepatitis C patients. J Hepatol 2003;39:655-6.